Obesity and prostate cancer risk according to tumor tmprss2:Erg gene fusion status

American Journal of Epidemiology

Volumn 181, Issue 9, 2015, Pages 706-713

  Egbers, Lieke ^a   Luedeke, Manuel ^a   Rinckleb, Antje ^a   Kolb, Suzanne ^a   Wright, Jonathan L ^a   Maier, Christiane ^a   Neuhouser, Marian L ^a   Stanford, Janet L ^a  

^a USA   (United States)

Author keywords

body mass index; ERG gene fusion; obesity; prostate cancer; TMPRSS2

Indexed keywords

ANDROGEN; PROSTATE SPECIFIC ANTIGEN; STEROID HORMONE; ERG PROTEIN, HUMAN; SERINE PROTEINASE; TMPRSS2 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN;

CANCER; DISEASE CONTROL; ENZYME ACTIVITY; GENE; HEALTH RISK; MATHEMATICAL ANALYSIS; OBESITY; TUMOR;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CANCER DIAGNOSIS; CANCER RISK; CONTROLLED STUDY; GENE; GENE FUSION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; OBESITY; POPULATION BASED CASE CONTROL STUDY; PROSTATE CANCER; PROSTATECTOMY; TMPRSS2 GENE; UNITED STATES; AGED; CASE CONTROL STUDY; COMPLICATION; GENETICS; MIDDLE AGED; PROSTATE TUMOR;

ADULT; AGED; BODY MASS INDEX; CASE-CONTROL STUDIES; HUMANS; MALE; MIDDLE AGED; OBESITY; ONCOGENE FUSION; PROSTATIC NEOPLASMS; SERINE ENDOPEPTIDASES; TRANS-ACTIVATORS;

EID: 84928911532     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwu344     Document Type: Article

References (44)

1. Perner S, Demichelis F, Beroukhim R, et al. TMPRSS2:ERG fusion-Associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 2006;66(17):8337-8341.
2. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer. 2008;8(7):497-511.
3. Tomlins SA, Bjartell A, Chinnaiyan AM, et al. ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol. 2009;56(2):275-286.
4. Minner S, Enodien M, Sirma H, et al. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res. 2011; 17(18):5878-5888.
5. Mosquera JM, Mehra R, Regan MM, et al. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res. 2009; 15(14):4706-4711.
6. Murakami K, Mavrothalassitis G, Bhat NK, et al. Human ERG-2 protein is a phosphorylated DNA-binding protein-A distinct member of the ETS family. Oncogene. 1993;8(6): 1559-1566.
7. Mao X, Yu Y, Boyd LK, et al. Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis. Cancer Res. 2010;70(13):5207-5212.
8. Setlur SR, Mertz KD, Hoshida Y, et al. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst. 2008;100(11):815-825.
9. Rubin MA, Maher CA, Chinnaiyan AM. Common gene rearrangements in prostate cancer. J Clin Oncol. 2011;29(27): 3659-3668.
10. Pettersson A, Lis RT, Meisner A, et al. Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERG. J Natl Cancer Inst. 2013;105(24):1881-1890.
11. De Pergola G, Silvestris F. Obesity as a major risk factor for cancer. J Obes. 2013;2013:Article 291546.
12. Golabek T, Bukowczan J, Ch?osta P, et al. Obesity and prostate cancer incidence and mortality: a systematic review of prospective cohort studies. Urol Int. 2014;92(1):7-14.
13. Hsing AW, Sakoda LC, Chua S Jr. Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr. 2007;86(3):s843-s857.
14. Stanford JL, Wicklund KG, McKnight B, et al. Vasectomy and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 1999;8(10):881-886.
15. Agalliu I, Salinas CA, Hansten PD, et al. Statin use and risk of prostate cancer: results from a population-based epidemiologic study. Am J Epidemiol. 2008;168(3):250-260.
16. Gleason DF. Histologic grading of prostate cancer: a perspective. Hum Pathol. 1992;23(3):273-279.
17. Summersgill B, Clark J, Shipley J. Fluorescence and chromogenic in situ hybridization to detect genetic aberrations in formalin-fixed paraffin embedded material, including tissue microarrays. Nat Protoc. 2008;3(2):220-234.
18. FitzGerald LM, Agalliu I, Johnson K, et al. Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer. BMC Cancer. 2008;8:230.
19. World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. (WHO Technical Report Series no. 894). Geneva, Switzerland: World Health Organization; 2000.
20. Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer: weighing the evidence. Eur Urol. 2013;63(5):800-809.
21. Discacciati A, Orsini N, Wolk A. Body mass index and incidence of localized and advanced prostate cancer-A dose-response meta-Analysis of prospective studies. Ann Oncol. 2012;23(7):1665-1671.
22. Giovannucci E, Rimm EB, Stampfer MJ, et al. Height, body weight, and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 1997;6(8):557-563.
23. Robinson WR, Stevens J, Gammon MD, et al. Obesity before age 30 years and risk of advanced prostate cancer. Am J Epidemiol. 2005;161(12):1107-1114.
24. Wright ME, Chang SC, Schatzkin A, et al. Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer. 2007;109(4):675-684.
25. Dal Maso L, Zucchetto A, La Vecchia C, et al. Prostate cancer and body size at different ages: an Italian multicentre case-control study. Br J Cancer. 2004;90(11):2176-2180.
26. Schuurman AG, Goldbohm RA, Dorant E, et al. Anthropometry in relation to prostate cancer risk in the Netherlands Cohort Study. Am J Epidemiol. 2000;151(6):541-549.
27. Discacciati A, Orsini N, Andersson SO, et al. Body mass index in early and middle-late adulthood and risk of localised, advanced and fatal prostate cancer: a population-based prospective study. Br J Cancer. 2011;105(7):1061-1068.
28. Robinson WR, Poole C, Godley PA. Systematic review of prostate cancers association with body size in childhood and young adulthood. Cancer Causes Control. 2008;19(8):793-803.
29. Littman AJ, White E, Kristal AR. Anthropometrics and prostate cancer risk. Am J Epidemiol. 2007;165(11):1271-1279.
30. Möller E, Adami HO, Mucci LA, et al. Lifetime body size and prostate cancer risk in a population-based case-control study in Sweden. Cancer Causes Control. 2013;24(12):2143-2155.
31. Mucci L, Ma J, Perner S, et al. Obesity and the TMPRSS2:ERG translocation in prostate cancer [abstract]. Cancer Prev Res. 2008;1(7 suppl):A91.
32. Wallner LP, Morgenstern H, McGree ME, et al. The effects of body mass index on changes in prostate-specific antigen levels and prostate volume over 15 years of follow-up: implications for prostate cancer detection. Cancer Epidemiol Biomarkers Prev. 2011;20(3):501-508.
33. Bhindi B, Margel D, Trottier G, et al. Obesity is associated with larger prostate volume but not with worse urinary symptoms: analysis of a largemultiethnic cohort. Urology. 2014;83(1):81-87.
34. Freedland SJ, Platz EA. Obesity and prostate cancer: making sense out of apparently conflicting data. Epidemiol Rev. 2007; 29:88-97.
35. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4(8):579-591.
36. Allan CA, McLachlan RI. Androgens and obesity. Curr Opin Endocrinol Diabetes Obes. 2010;17(3):224-232.
37. Fernández-Serra A, Rubio-Briones J, García-Casado Z, et al. Prostate cancer: the revolution of the fusion genes [in Spanish]. Actas Urol Esp. 2011;35(7):420-428.
38. Iljin K, Wolf M, Edgren H, et al. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res. 2006;66(21): 10242-10246.
39. Lin C, Yang L, Tanasa B, et al. Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell. 2009;139(6):1069-1083.
40. Bastus NC, Boyd LK, Mao X, et al. Androgen-induced TMPRSS2:ERG fusion in nonmalignant prostate epithelial cells. Cancer Res. 2010;70(23):9544-9548.
41. Haffner MC, Aryee MJ, Toubaji A, et al. Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet. 2010;42(8): 668-675.
42. Mani RS, Tomlins SA, Callahan K, et al. Induced chromosomal proximity and gene fusions in prostate cancer. Science. 2009; 326(5957):1230.
43. Hsing AW, Chu LW, Stanczyk FZ. Androgen and prostate cancer: is the hypothesis dead? Cancer Epidemiol Biomarkers Prev. 2008;17(10):2525-2530.
44. Pettersson A, Graff RE, Bauer SR, et al. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-Analysis. Cancer Epidemiol Biomarkers Prev. 2012;21(9):1497-1509.